These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33790164)

  • 41. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
    Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
    Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
    di Sebastiano P; Grottola T; di Mola FF
    Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Borderline resectable pancreatic cancer.
    Hackert T; Ulrich A; Büchler MW
    Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
    Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
    Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
    Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
    J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis.
    Kim BR; Kim JH; Ahn SJ; Joo I; Choi SY; Park SJ; Han JK
    Eur Radiol; 2019 Jan; 29(1):362-372. PubMed ID: 29931561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
    Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
    Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: Pathological local invasion and microvessel invasion analysis.
    Naito Y; Ishikawa H; Sadashima E; Okabe Y; Takahashi K; Kawahara R; Hisaka T; Fukahori M; Ushijima T; Ishida Y; Tanigawa M; Mihara Y; Nakayama M; Kondo R; Kusano H; Takase Y; Abe H; Ogo E; Okuda K; Shimamatsu K; Yano H; Akiba J
    Mol Clin Oncol; 2019 Sep; 11(3):225-233. PubMed ID: 31423309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A Successful Case of Pancreaticoduodenectomy after Neoadjuvant Therapy for Pancreatic Head Cancer with Acute Pancreatitis Due to Iatrogenic Injury of the Pancreatic Duct].
    Chiba K; Mizuma M; Motoi F; Hayashi H; Aoki S; Hata T; Takadate T; Kawaguchi K; Masuda K; Ishida M; Ohtsuka H; Nakagawa K; Morikawa T; Kamei T; Unno M
    Gan To Kagaku Ryoho; 2021 Jan; 48(1):118-120. PubMed ID: 33468740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma.
    Eid M; Ostřížková L; Kunovský L; Brančíková D; Kala Z; Hlavsa J; Janeček P; Kosíková I; Blažková M; Slabý O; Mayer J
    Neoplasma; 2021 Jan; 68(1):1-9. PubMed ID: 32880468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A Case of Locally Advanced Pancreatic Cancer Showing R0 Resection after Resection of the Portal Vein Following Preoperative Chemoradiotherapy].
    Nakano R; Satoh D; Tokumoto N; Chouda Y; Kanazawa T; Takada S; Harano M; Matsukawa H; Ojima Y; Idani H; Shiozaki S; Okajima M; Ninomiya M
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):459-61. PubMed ID: 27220794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy.
    Joo I; Lee JM; Lee ES; Ahn SJ; Lee DH; Kim SW; Ryu JK; Oh DY; Kim K; Lee KB; Jang JY
    AJR Am J Roentgenol; 2018 May; 210(5):1059-1065. PubMed ID: 29489408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease.
    Cassinotto C; Dohan A; Zogopoulos G; Chiche L; Laurent C; Sa-Cunha A; Cuggia A; Reinhold C; Gallix B
    Eur J Radiol; 2017 Oct; 95():33-38. PubMed ID: 28987689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases.
    Wang G; Zhou D
    Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemoradiotherapy.
    Matsuki H; Hiroshima Y; Miyake K; Murakami T; Homma Y; Matsuyama R; Morioka D; Kurotaki D; Tamura T; Endo I
    J Hepatobiliary Pancreat Sci; 2021 Feb; 28(2):174-182. PubMed ID: 33316125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.